Skip to Main Content
Pitt Home
Find People
School of Medicine
Toggle navigation
Skip Navigation Links
Home
About
Leadership
Mission
Department Statistics
Building Information
Thomas E. Starzl BST
Biomedical Science Tower 3
Directory
Primary Faculty
Secondary Faculty
Graduate Students
Fellows
Administrative Staff
Research Staff
Adjunct Faculty
Department Alumni
Research
Research Areas
Labs
Equipment
Funding Opportunities
Faculty Development Program
Responsible Conduct of Research
Shops
Cell Biology/Pharmacology Machine Shop
Education
Molecular Pharmacology Graduate Program
Current Students
Current Student Roster
Student Publications
Diversity, Accessibility, and Counseling
Student Awards
MPGP News
Prospective Students
Welcome from the Director
Research Opportunities
PhD Track
MD/PhD Track
Financial Aid
Graduate Faculty
Graduate Courses
Grad Student Lab Rotations
Grad Student Events
Grad Student Event Calendar
Graduate Student Event Schedule
Alumni/Career Development
Alumni
Alumni Contacts
Molecular Pharmacology Facebook Group
Molecular Pharmacology Student-Alumni Network (LinkedIn)
SOM Graduate Studies - Career and Professional Development
Executive Committee
Student Testimonials
IBGP
Grad Student Funding Opportunities
NIH T32 Training Grant
Outcomes
Predoctoral Fellowship
Admissions
Student Handbook & General Timeline
Links
Useful Links
School of Medicine
PubMed
Remote Resources
Biomedical Masters Program
Undergraduate Research
Summer Fellowships
Lab Rotations
Graduate Fellowships
News
Events
Calendar
Seminar Series
Links
Contact
Opportunities
Department
PORtal
Computer Resources Access Request
IT-Equipment-Facilities Support Request
Poster Requests
Reservation Calendars
Badge Access Request
Home
>
Research
>
Labs
>
Wang (Man-Tzu) Lab
Wang (Man-Tzu) Lab
Current Members
Research
Alumni
Publications
Man-Tzu Wang, PhD
Ras proteins comprise a family of signal-transducing GTPases that are frequently mutated in human cancers. Oncogenic Ras mutations lock the protein in its GTP-bound form thus permitting its constitutive interaction with and activation of multiple effectors. The pathogenic mutations on KRAS, present in over 90% of pancreatic ductal adenocarcinomas (PDAC), 45% of colorectal cancers and 35% of lung adenocarcinomas, are the major driver of their poor outcomes and failure to respond to targeted therapies. However, unlike many other driver oncoproteins being successfully exploited as targets of therapeutic intervention, KRAS has not yielded to any types of therapeutic attacks and been considered as “undruggable” for many years. The goal of the Wang lab at the Hillman Cancer Center is to understand how KRAS drives malignancies in cells and to identify novel molecular targets of intervention to improve the clinical outcomes of KRAS-driven cancers.
KRAS and stemness in cancers
The three closely related human RAS, H-Ras
,
N-Ras
, and
K-Ras
genes, share a high degree of sequence homology as well as identical regulators and effectors. However, they also have unique roles in physiological and pathological processes.
K-Ras
mutations occur at high frequency in pancreatic and colorectal cancers and in lung adenocarcinomas, while
N-Ras
and
H-Ras
mutations are far less common. Furthermore,
K-Ras
deficiency results in embryonic lethality, whereas
N-
and
H-Ras
knockout mice develop normally. Our lab has defined that KRAS, but not HRAS, promotes cancer stem cell-like properties in the model of pancreatic cancer. We will continue to investigate 1) the roles of KRAS in cancer stemness/plasticity; and 2) the stemness-associated genetic, epigenetic, and
transcriptomic
signatures in KRAS-induced cancers.
Targeting novel regulatory mechanisms and effectors of KRAS
KRAS proteins does NOT appear to present suitable pockets to which drugs could bind, except for the GDP/GTP binding site: unfortunately, Ras proteins bind very tightly to these nucleotides (picomolar affinities and slow off-rates) making the prospect of identifying competitive nucleotide analogs seem virtually impossible. As a substitute for direct attack on the KRAS protein itself, our group has been and will be investigating the upstream and downstream pathways specific to KRAS, in the hope that blocking these pathways will provide clinical benefit for cancer patients suffering with Ras mutations.
Interruption of an autocrine circuit induced by oncogenic KRAS
RAS-induced inflammatory cytokine circuits promote cell transformation, tumor cell survival, angiogenesis, and metastasis in multiple types of cancers via activation of NF-
k
B, STAT3 or other pathways, but their relevance in KRAS-mutated solid tumors is not completely understood. Our group has found that expression of LIF, the most pleiotropic member of the IL-6 family that activates the STAT3 pathway, is stimulated by oncogenic KRAS in PDAC. Depletion of LIF by genetic means or neutralization of LIF by antibody reduces PDAC tumor engraftment in xenograft models. Moreover, LIF-neutralizing antibody synergizes with gemcitabine to eradicate established pancreatic tumors in a syngeneic, KrasG12D-driven mouse model of PDAC. The data suggest a crucial role of LIF in KRAS-driven pancreatic cancer. Blockade of LIF may represent an attractive approach to improve the therapeutic outcome of traditional
chemotherapy of pancreatic cancer. In the future, we will use cell-based assays and multiple genetically engineered mouse models (GEMMs) to study 1) the functions of LIF in more KRAS-induced cancer models, including lung cancer; 2) how KRAS regulates LIF expression in cancers; 3) differential roles of LIF and other IL-6 family cytokines in KRAS-cancers; and 4) immune responses mediated by LIF in the tumor microenvironment of KRAS-induced cancers.
Link to lab website:
www.thewanglabpitt.org
Man-Tzu Wang, PhD
Assistant Professor
Man-Tzu Wang, PhD
Journal Articles
Wang MT
, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, and McCormick F. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS-driven pancreatic cancer. Nat Commun 10:3055, 2019.
Wang MT
, Holderfield M, Gales J, Delrosario R, To M, Balmain A, McCormick F. KRas promotes tumorigenicity through suppression of non-canonical Wnt signaling. Cell 163:1237-1251, 2015.
MT Wang
, H Jiang, D Boral and D Nie. Cancer Stem Cells in Resistance to Cytotoxic Drugs: Implications in Chemotherapy. B. Bonavida (ed.), Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy, Resistance to Targeted Anti-Cancer Therapeutics 1, DOI: 10.1007/978-1-4614-7070-0_8, Springer Science+Business Media New York 2013.
Yang D*,
Wang MT
*
, Tang Y, Chen Y, Jiang H, Jones TT, Rao K, Brewer GJ, Singh KK, Nie D. Impairment of mitochondrial respiration in mouse fibroblasts by oncogenic H-RAS(Q61L). Cancer Biol Ther 9:122-133, 2010. (*Shared first author).
Wang MT
, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 26:525-534, 2007.